Skip to main content

Howze Yalonda's Form 4 filing

Codiak BioSciences, Inc.CDAK · filed Jan 23, 2023

Accession no.
0000899243-23-002395
Filed
Jan 23, 2023
Trade date
Jan 19-20, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $876.96. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Howze YalondaCIK 0001828153Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 19, 2023Common StockMOption exerciseAcquired+4,000–F1–4,000Direct
Jan 20, 2023Common StockSSaleDisposed−1,512$0.58−$876.962,488Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 19, 2023Common StockMOption exerciseDisposed−4,000$0.00$08,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

Remarks

Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary

Read the full filing on SEC EDGAR (opens in a new tab)